Researchers Find Biomarker for Dementia
Researchers at the DZNE and the University Medical Center Göttingen (UMG) have identified molecules in the blood that can indicate impending dementia.
Category: Dementias & Alzheimer’s
Dementias & Alzheimer’s
Latest
Dementias & Alzheimer’s
Latest
Detecting Alzheimer’s Gets Easier with a Simple Blood Test
Blood tests show promise in diagnosing Alzheimer’s with less cost and less burdensome procedures, and could be used to identify patients for trials of potential drugs, reports Scientific American.
Dementias & Alzheimer’s
Latest
Quanterix Offers P-Tau 181 Kit for Detection and Study of Alzheimer’s Disease
Research suggests the biomarker could be critical to predicting Alzheimer’s disease progression and differentiating the disease from other disorders.
Companies Embark on Partnership for Neurodegenerative Disease Research
Quanterix will join forces with UmanDiagnostics to provide commercial access to an ultrasensitive single molecule array for the detection of neurofilament light in blood specimens.
Read More
Bomb Detecting Technology Applied for Early Dementia Diagnosis
The new detection technique uses optical fiber and a laser to collect the signature of certain molecules.
Read More
Affymetrix, XRGenomics Collaborate to Develop Diagnostic Tests for Age-Related Diseases
XRGenomics is using Affymetrix technology to develop gene expression-based signatures for translational research and biomarker test development in areas such as dementia, Alzheimer’s, and other age-related diseases.
Read More
Personalized Medicine Progresses
Notable breakthroughs in personalized medicine continue, but reimbursement hurdles and regulation concerns have posed occasional setbacks.
Read More
Mayo Clinic Study: Blood Biomarker Could Mark Severe Cognitive Decline, Hasten Progression Among Parkinson’s Patients
The Mayo Clinic lab is researching blood-based biomarkers for Parkinson’s disease because blood tests are less invasive and cheaper than a brain scan or spinal tap, other tools used to research the disease.
Read More
Have You Ever Pondered Why We All Don’t Get Alzheimer’s Disease?
One might think the brains of people who develop Alzheimer’s disease possess building blocks of the disease absent in healthy brains, but for most sufferers, this is not true.
Read More
From the Editor: April 2013: It’s Not All in Your Head
A nod to advances in testing for neurological disorders, and the long road ahead toward broader genetic testing.
Read More
Quest Offers Dementia Dx Panel for Treatable Forms of Cognitive Impairment
The test panel is believed to be the first commercial service from a clinical laboratory to combine several guideline-recommended tests for identifying secondary, treatable causes of dementia as a single blood test and report.
Read More
Merck, Luminex to Develop CDx for Alzheimer’s
Luminex will be responsible for development, regulatory submission, and commercialization of the candidate companion diagnostic device, which will employ Luminex’s xMAP Technology.
Read MoreAmarantus BioScience Licenses LymPro Alzheimer’s Disease Diagnostic Blood Test
Amarantus BioScience Inc announced that it has licensed the LymPro Alzheimer’s Disease Diagnostic Blood Test (LymPro) from Memory Dx, LLC (MDx), formerly known as Provista Life Sciences Inc.
Read More
Measuring Metabolism Can Predict the Progress of Alzheimer’s with 90% Accuracy, Study Says
Metabolic studies could lead to new therapies, says a Tel Aviv University researcher.
Read MoreExceeding Expectations
Vista Clinical Diagnostics offers the industry’s most advanced testing, and recently introduced a partnership program for smaller and medium-size labs. Davian Santana, president, and Nathan Hawkins, vice president. What if your favori
Read MoreAlzheimers Challenge 2012 Unveiled at Care Innovations Summit
he Alzheimer’s Challenge 2012 calls for inventive concepts to help improve the diagnostic identification and tracking of Alzheimer’s disease.
Read More
News Story #15302
Positive Early Results for Parkinson’s Treatment Michael J. Fox Harbor BioSciences, San Diego, which is investigating the use the company’s proprietary compound Triolex as a treatment for Parkinson’s disease (PD) with fund
Read MoreAchievement Reached In Diagnostic Blood Test For Alzheimer’s Disease
BiOasis announces completion of a project intended to produce proprietary monoclonal antibodies for its Cognitest blood test for Alzheimer’s disease.
Read More